Futibatinib (Lytgobi®) Adverse Effects and Supportive Care Management

The Fibroblast Growth Factor Receptor (FGFR) pathway plays a key role in multiple fundamental cellular processes. The FGFR inhibitor futibatinib (Lytgobi®) is approved for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements.1 The FGFR inhibitor drug class carries specific adverse effect profiles and monitoring considerations. The purpose of this PQI is to outline adverse effects of futibatinib (Lytgobi®) and provide recommendations to educate, monitor, and support patients appropriately.